Mergers & Acquisitions ·
Standard BioTools entered into a Termination, Waiver and Release Agreement with Illumina, receiving approximately $30…
LABStandard Biotools Inc.
Standard BioTools entered into a Termination, Waiver and Release Agreement with Illumina, receiving approximately $30 million in cash to waive the 2026 earnout and terminate related royalty and license agreements. Simultaneously, the Company signed a Share and Asset Purchase Agreement to sell its mass cytometry business to Multiplex Bio for up to $10 million, consisting of a $5 million promissory note and a potential $5 million milestone payment. The transaction requires Multiplex Bio to secure a senior secured working capital loan or receive a working capital loan from Standard BioTools of up to $10 million. These strategic moves support the pending merger with Treeline Biosciences, which received early FTC clearance. Standard BioTools operates in the life science tools industry, providing next-generation solutions for biomedical research.